Lupin launches Clobazam oral suspension in US
The company has launched its Clobazam oral suspension 2.5mg/mL after having received approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
New Delhi: Drug firm Lupin Friday said it has launched generic Clobazam oral suspension, used for the treatment of seizures associated with a severe form of epilepsy, in the US market.
The company has launched its Clobazam oral suspension 2.5mg/mL after having received approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
This medication is used with other medications to help control seizures. It belongs to a class of medications called benzodiazepines, which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
Read Also: Lupin gets FDA nod for Fluoxetine to treat depressive disorders
The product is the generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, 2.5mg/mL, it added.
As per IQVIA MAT December 2018 data, Clobazam oral suspension 2.5mg/mL had annual sales of USD 253 million in the US, Lupin said.
Read Also: Lupin gets USFDA nod to Tadalafil to treat pulmonary arterial hypertension
"It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older," the company added.
Lupin is a pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a position in the Anti-TB segment.
Read Also: Lupin gets 2 observations from USFDA for its Goa facility
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd